GABA receptor (GABAR) types C (GABA C R) and A (GABA A R) are both GABA-gated chloride channels that are distinguished by their distinct competitive antagonist properties. The structural mechanism underlying these distinct properties is not well understood. In this study, using previously identified binding residues as a guide, we made individual or combined mutations of nine binding residues in the 1 GABA C R subunit to their counterparts in the ␣ 1 ␤ 2 ␥ 2 GABA A R or reverse mutations in ␣ 1 or ␤ 2 subunits. The mutants were expressed in Xenopus laevis oocytes and tested for sensitivities of GABA-induced currents to the GABA A and GABA C receptor antagonists. The results revealed that bicuculline insensitivity of the 1 GABA C R was mainly determined by Tyr106, Phe138 and Phe240 residues.
Gabazine insensitivity of the 1 GABA C R was highly dependent on Tyr102, Tyr106, and Phe138. The sensitivity of the 1 GABA C R to 3-aminopropyl-phosphonic acid and its analog 3-aminopropyl-(methyl)phosphinic acid mainly depended on residues Tyr102, Val140, FYS240 -242, and Phe138. Thus, the residues Tyr102, Tyr106, Phe138, and Phe240 in the 1 GABA C R are major determinants for its antagonist properties distinct from those in the GABA A R. In addition, Val140 in the GABA C R contributes to 3-APA binding. In conclusion, we have identified the key structural elements underlying distinct antagonist properties for the GABA C R. The mechanistic insights were further extended and discussed in the context of antagonists docking to the homology models of GABA A or GABA C receptors.
The GABA A and GABA C receptors are both GABA-gated chloride channels but have distinct antagonist properties. The selective antagonism forms the basis for their classification. In fact, the GABA C R was defined as the GABA receptor that is insensitive to GABA A competitive antagonist bicuculline and GABA B receptor agonist baclofen (Drew et al., 1984; Johnston, 1996) . In addition to bicuculline, GABA A Rs can be antagonized by gabazine (SR95531). In contrast, GABA C Rs are much less sensitive to gabazine but can be selectively antagonized by (1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid (not available in the United States; Murata et al., 1996; Ragozzino et al., 1996) , 3-aminopropyl(methyl) phosphinic acid (3-APMPA), and 3-aminopropylphosphonic acid (3-APA) (Johnston, 1996) . Distinct antagonist profiles of the GABA A and GABA C Rs indicate that their agonist/antagonist binding pockets are not the same. However, the structural basis for the distinct antagonist profiles of these two receptor types is not known.
Molecular cloning has identified at least 18 GABA receptor subunits in the nervous system (Barnard et al., 1998) . They all belong to the cys-loop receptor family of the ligand-gated ion channels (Lester et al., 2004) . A typical GABA A R can be formed by exogenously coexpressing ␣, ␤, and ␥ subunits with two ␣ subunits, two ␤ subunits, and one ␥ subunit in a receptor (Chang et al., 1996) . The ␣ 1 ␤ 2 ␥ 2 is the most abundant subtype of GABA A Rs in the central nervous system (Whiting et al., 2000) . The GABA C Rs seemed to be mainly formed by subunits (Zhang et al., 2001) . When exogenously expressed, the 1 GABA receptor subunit can form functional channels with the GABA C R pharmacological properties (Cutting et al., 1991) . Studies in the past 2 decades with photoaffinity labeling, site-directed mutagenesis, and the substituted cysteine accessibility method have shaped relatively complete models for the extracellular agonist/antagonist binding pockets of ␣␤␥ GABA A R (Sigel et al., 1992; Amin and Weiss, 1993; Smith and Olsen, 1994; Westh-Hansen et al., 1997 Boileau et al., 1999; Boileau et al., 2002; Holden and Czajkowski, 2003; Newell and Czajkowski, 2003) and the 1 GABA C R (Amin and Weiss, 1994; Lummis et al., 2005; Sedelnikova et al., 2005; Harrison and Lummis, 2006) . In the structural model of the GABA A R, residues in six loops (segments) designated A through F have been identified to form the agonist/antagonist binding pocket in the subunit interface between ␤ and ␣ subunits. The ␤ subunit contributes the binding loops A, B, and C. The ␣ subunit contributes the binding loops D, E, and F. In contrast, the agonist/antagonist binding pocket of the 1 GABA C R is formed in the subunit interface between two 1 subunits with five binding loops (A-E) identified (Sedelnikova et al., 2005) . Figure 1 shows the aligned sequences of the binding loops in the GABA A and GABA C subunits. Note that the loop C of the 1 subunit has one insertion (Ser242), which is close to an additional binding residue (Tyr241) in the same loop (Amin and Weiss, 1994 ). This alignment is further supported by our preliminary result that the receptor was not functional with three residues (Phe240 -Ser242) of the 1 subunit replaced by the corresponding residues in the ␤ 2 subunit with previous alignment (data not shown). However, with a double mutation and a deletion (F240VϩTyr241FϩS242⌬), the receptor was functional. For convenience, we refer to this F240VϩTyr241FϩS242⌬ mutant as a single mutant: FYS240VF. Other distinct binding residues in the GABA A and GABA C R subunits are apparent in the sequence alignment. Except for the residues in the extended loop E, which apparently do not face the binding pocket, the other nine distinct binding residues could potentially contribute to distinct antagonist pharmacology between GABA A and GABA C Rs. These residues include Tyr102 and Tyr106 in loop D, Phe138 and Val140 in loop A, Ser168 in loop E, Tyr241 in loop C, and Leu216, Thr218 and Arg221 in loop F of the 1 GABA C R subunit.
In this study, we substituted the distinct residues of the 1 GABA C R subunit, indicated by arrowheads in Fig. 1 , with the corresponding residues in the GABA A R ␤ 2 (for loops A and C) or ␣ 1 (for loops D, E, and F) subunits individually or in combinations. When these mutants were expressed in Xenopus laevis oocytes, they formed functional channels with altered sensitivities to agonists and antagonists. By testing antagonist sensitivity of agonist-induced current in these mutants, we have identified key structural elements underlying distinct antagonist properties for the GABA A and GABA C Rs. The mechanistic insights for the selective interactions between the antagonists and two types of receptors were further discussed in the context of antagonist dockings to the homology models of the GABA A or GABA C Rs.
Materials and Methods
Mutagenesis and cRNA Preparation. The cDNA encoding human 1 GABA receptor subunit and rat ␣ 1 , ␤ 2 , and ␥ 2 GABA receptor subunits were kindly provided by Dr. David S. Weiss. Note that the rat GABA receptor subunits are highly homologous (98-99%) to their human counterparts. In fact, in all binding loops, these rat and human GABA receptor subunits are virtually identical. All subunits were cloned into the oocyte expression vector pGEMHE with T7 orientation. The residues in the amino-terminal segments corresponding to loops A, C, D, E, and F in the 1 GABA receptor subunit were mutated to their homologous residues in the ␣ 1 or ␤ 2 GABA receptor subunits, individually or in combination, using the polymerase chain reaction-based QuikChange method of site-directed mutagenesis following the manufacturer's protocol (Stratagene, La Jolla, CA). The mutations were confirmed by automated DNA sequencing. The wild-type and mutant cDNAs were then linearized by NheI digestion. The cRNAs were transcribed with a standard in vitro transcription protocol as described previously (Sedelnikova et al., 2005) . The cRNA yield and integrity were examined on a 1% agarose gel. cRNA concentration was further quantitated with an Eppendorf BioPhotometer (Eppendorf North America, New York, NY).
Oocyte Preparation and RNA Injection. Female X. laevis frogs (Xenopus I, Ann Arbor, MI) were anesthetized by 0.2% MS-222. The ovarian lobes were surgically removed from the frog and placed in the incubation solution, consisting of 82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 1 mM Na 2 HPO 4 , 0.6 mM theophylline, 2.5 mM sodium pyruvate, 5 mM HEPES, 50 g/ml gentamicin, 50 U/ml penicillin, and 50 g/ml streptomycin, pH 7.5. The frog was then given the analgesic xylazine hydrochloride (10 mg/kg i.p.) and allowed to recover from surgery in shallow water before being returned to the incubation tank. The lobes were cut into small pieces and digested with 1 Wü nsch unit/ml Liberase Blendzyme 3 (Roche Applied Science, Indianapolis, IN) with constant stirring at room temperature for 1.5 to 2 h. The dispersed oocytes were thoroughly rinsed with the above solution. The stage VI oocytes were selected and incubated at 16°C before injection. Micropipettes for injection were pulled from borosilicate glass (Drummond Scientific, Broomall, PA) on a horizontal puller (P87; Sutter Instrument Company, Novato, CA), and the tips were cut with forceps to Ϸ40 m in diameter. The cRNA was drawn up into the micropipette and injected into oocytes Fig. 1 . Design of mutations based on the distinct binding residues in the GABA A and GABA C Rs. Sequence alignment of the amino-terminal domains of the GABA A (␣ 1 , ␤ 2 ) and GABA C ( 1 ) receptor subunits with binding sites in bold. Except for an extended region of loop E (first three binding residues in loop E) that appears to not face the binding pocket in the structure model (Sedelnikova et al., 2005) , all other distinct binding residues are potential binding residues underlying distinct antagonist pharmacological properties between the GABA A and GABA C Rs. The residues pointed by arrowheads are the residues under investigation. with a Nanoject microinjection system (Drummond Scientific) at a total volume of 20ϳ60 nl. Two-Electrode Voltage-Clamp. One to 3 days after injection, the oocyte was placed in a homemade small-volume chamber with continuous perfusion with oocyte Ringer's solution, which consisted of 92.5 mM NaCl, 2.5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, pH 7.5. The chamber was grounded through an agar bridge. The oocytes were voltage-clamped at Ϫ60 mV to measure GABAinduced currents using a GeneClamp 500B (Axon Instruments, Foster City, CA). The current signal was low-pass filtered at 10 Hz with the built-in low-pass Bessel filter in the GeneClamp 500B and digitized at 20 Hz with Axon Digidata1320 and pClamp9 (Molecular Devices, Sunnyvale, CA) in a Dell desktop computer. For the antagonist sensitivity test, GABA-induced current with an ϳEC 20 concentration, the concentration that induces 20% of maximum current, for each mutant was inhibited with coapplication of an antagonist with increasing concentrations. The antagonist IC 50 (the concentration that inhibits 50% of GABA-induced current) was then determined by fitting concentration-dependent inhibition data with a Hill inhibition equation using Prism 4 software (GraphPad Software, San Diego, CA). The IC 50 values were further used to calculate antagonist apparent affinity K i for different mutants by the following equation: (Newell and Czajkowski, 2003) .
Drug Preparation. GABA (SigmaAldrich, St. Louis, MO) stock solution (100 mM) was prepared daily from solid. (Ϫ)-Bicuculline methiodide (Tocris Bioscience, Ellisville, MO), gabazine (SR95531; Tocris), 3-APMPA (SKF97541; Tocris), and 3-APA (SigmaAldrich) stock solutions (20, 25, 100, and 100 mM, respectively) were prepared and stored at Ϫ20°C in aliquots before use.
Data Analysis. The dose-response relationship of the GABAinduced current in recombinant GABA A/C receptors was leastsquares fit to a Hill equation with Prism 4.0 (GraphPad Software) to derive EC 50 , Hill coefficient (the slope factor), and maximum current. The dose-dependent inhibition by competitive antagonists was fitted to a Hill inhibition equation to derive IC 50 , Hill coefficient, and maximal current. The maximum current was then used to normalize the dose-response/-inhibition curve for each individual oocyte. The averages of the normalized currents were used to plot the data. All the data were presented as mean Ϯ S.E.M. (standard error of the mean).
Homology Modeling. The three-dimensional model of the pentameric extracellular domains of the 1 GABA receptor was made previously (Sedelnikova et al., 2005) . The three-dimensional model of ␣ 1 ␤ 2 ␥ 2 GABA receptor extracellular domain was built using Discovery Studio 1.7 software (Accelrys, San Diego, CA) running in a Dell Precision 690 computer (Dell, Austin, TX) with the homology model of the 1 GABA receptor as the template to ensure that two homology models converge in a similar way for better comparison. In brief, amino-terminal domains of the rat GABA receptor subunits (␤ 2 ␣ 1 ␤ 2 ␣ 1 ␥ 2 ) were aligned to the human 1 sequences (chains A to E) with the modeler in the Discovery Studio Modeler 9 using "Align Sequence with Structure" protocol (Sali and Blundell, 1993) with blosum62 scoring matrix, gap open penalty of Ϫ100, gap extension penalty of Ϫ10, and default two-dimensional gap weights. The homology models were then built using "Building Homology Models" (Sali and Blundell, 1993 ). The pentameric model was further energy minimized for 400 steps of the "Steepest Descent" minimization followed by 1000 steps of "Conjugated Gradient" minimization using "Minimization" protocol with CHARMm force field. The model of mutant receptor with mutation(s) in the binding regions was generated with "Build Mutant" protocol and energy minimized as above.
Ligand Docking. The three-dimensional ligand structures of bicuculline, gabazine, 3-APA, and 3-APMPA were downloaded, as MDL molecule files, from the ChemIDplus National Institutes of Health web site (http://chem.sis.nlm.nih.gov/chemidplus/). The receptor subunit dimers were saved from original pentameric models. The docking of flexible ligands to the putative binding pockets of the GABA A (in the interface between ␤ 2 and ␣ 1 subunits) or GABA C (in the interface between two 1 subunits) receptors was performed with "Dock Ligands (LigandFit)" protocol (Venkatachalam et al., 2003) in the Discovery Studio 1.7 software (Accelrys, San Diego, CA). The docking results were scored with all available scoring functions, which include DockScore [ϭ Ϫ(ligand/receptor interaction energy ϩ ligand internal energy)], LigScore1 and LigScore2 (Krammer et al., 2005) , Ludi1 (Böhm, 1994) and Ludi2 (Böhm, 1998) , Piecewise Linear Potential 1 (Gehlhaar et al., 1995) and Piecewise Linear Potential 2 (Gehlhaar et al., 1999) , potential of mean force (Muegge and Martin, 1999) , and Jain (Jain, 1996) . The poses with the highest DockScores tended to have highest scores in other functions, although the scores from these scoring functions in different poses were only partially correlated (data not shown). Thus, the poses with highest DockScores and the lowest ligand internal energy were used for presentation unless specified otherwise. The docking success [with output pose(s)] was determined by pose saving thresholds. We used default values of Pose Saving Dockscore Threshold (0.0), Pose Saving RMS Threshold for Diversity (1.50), and Pose Saving Score Threshold for Diversity (20.0). A docking without any output pose is considered as a failure.
Results
Bicuculline Sensitivity. Bicuculline insensitivity is the major distinction of GABA C Rs from GABA A Rs. To search for the structural basis underlying this difference, we first made individual mutations, except for Tyr241 (FYS240VF), in nine distinct binding site residues in the 1 GABA C R to their counterparts in the ␣ 1 or ␤ 2 GABA A R subunits. When expressed in X. laevis oocytes, all nine individual mutant 1 GABA receptors resulted in functional channels with slightly altered GABA sensitivity (with maximum of 24-fold reduction). The EC 50 values and maximal currents (I max s) derived from GABA dose-response relationships of these mutants are listed in Table 1 . The GABA-induced current with an ϳEC 20 GABA concentration was then used to test bicuculline sensitivity of these mutants. Figure 2A represents the dose-dependent inhibition of the GABA-induced currents by bicuculline in the wild-type and single mutant 1 GABA receptors. Note that although the wild-type 1 GABA C R was essentially insensitive to bicuculline, three (of nine) mutants (Y106S, F138Y and FYS240VF) exhibited slightly increased sensitivity to bicuculline ( Fig. 2A) . At the highest concentrations tested, bicuculline blocked nearly one half of the GABAinduced currents in these three mutants. Due to incomplete inhibition (Ͻ50%) at the highest concentrations tested, the IC 50 values could not be reliably determined. They were clearly slightly higher than the highest concentrations tested in these three mutants. The range of IC 50 values and derived apparent affinity K i are listed in Table 2 . The result suggests that these three mutants are potential candidates for further investigation.
By making single mutations at these nine distinct binding residues in the 1 GABA C R subunit, we were clearly unable to dramatically increase binding affinity to bicuculline. However, we could potentially achieve this goal by combining several promising individual mutants. To test this, we made double and triple mutants with combinations of the three promising individual mutants. Figure 2B represents bicuculline dose-inhibition for the combinations of these promising mutants along with one nonpromising mutant as a control. Double mutations (Y106Sϩ FYS240VF, Y106SϩF138Y, F138YϩFYS240VF) clearly in- Table 2 ), which was only severalfold lower than the bicuculline sensitivity of the wild-type GABA A R (K i ϭ 5.21 Ϯ 0.74 M, Table 2 ). Thus, mutations of these residues to their homologous residues in the GABA A R are enough to confer bicuculline sensitivity to the 1 GABA C R. These residues must synergistically contribute to bicuculline affinity, although we cannot role out the contribution of other binding and "nonbinding" residues to bicuculline binding. For individual contributions of the residues Phe240 and Tyr241 in FYS240VF mutant, please see Discussion.
Gabazine Sensitivity. Like bicuculline, gabazine is also a relatively selective GABA A R antagonist, although their structures are quite different. In fact, gabazine has a nanomolar affinity for GABA A R. However, the wild-type 1 GABA C R was still sensitive to gabazine but with a much lower affinity (K i ϭ 57.84 Ϯ 7.66 M) compared with K i ϭ 0.12 Ϯ 0.01 M in the wild type GABA A R (Table 3 ). Figure 3A represents gabazine dose-inhibition relationships in nine individual mutants of the 1 GABA receptor. Note that whereas FYS240VF mutation increased apparent affinity by only ϳ2-fold, the other three mutants (Y102F, Y106S, and F138Y) exhibited a larger increase in gabazine affinity (with decreased K i ; Table 3 ). Combination of Y102F, Y106S, and F138Y resulted in a receptor with a much lower K i (1.61 Ϯ 0.03 M) despite a dramatic increase in GABA EC 50 (156.46 Ϯ 10.73 M) for this mutant receptor. Thus, residues Tyr102, Tyr106, and Phe138 are major contributors to gabazine binding. Other minor contributors include Ser168 and Thr218. Mutations of them increased gabazine affinity by approximately 5-fold.
3-APA and 3-APMPA Sensitivity. 3-APA and its methylated analog 3-APMPA are selective competitive antagonists for GABA C over GABA A Rs (Johnston, 1996) , although they are also GABA B receptor agonists (Froestl et al., 1995) . Mutants Y102F, V140L, and FYS240VF exhibited the most dramatic reduction of apparent affinity to the GABA C R competitive antagonist 3-APA (11-, 32-, and 25-fold reduction, respectively, Fig. 4A and Table 4 ). Thus, bicuculline and 3-APA both interact with three binding loops (D, A, and C) but with slightly different residues in loops D and A. We predicted that when all three residues are mutated, the sensitivity to 3-APA should be further reduced. Indeed, the triple mutant Y102FϩVal140LϩFYS240VF exhibited 77-fold reduction in sensitivity to 3-APA ( Fig. 4B and Table 4 ).
Because the triple mutant is still slightly sensitive to 3-APA (K i ϭ 844.88 Ϯ 100.67 M), we then combined two additional mutations (Y106S and F138Y) to the receptor. When the quintuple mutant was expressed, it exhibited bicuculline sensitivity (although reduced compared with the triple mutant; Table 2 ) and 3-APA insensitivity (Fig. 4C) . Further reduction of 3-APA sensitivity in the quintuple mutant could be due to the contribution of F138Y mutation, which reduced 3-APA sensitivity by 7.5-fold when singly mutated. Thus, we have identified five residues in the binding site that conferred GABA C properties to the 1 GABA receptor, and Note that although we injected similar amount of RNA for all constructs, the expression levels were not strictly controlled because of batch-to-batch variability of oocytes and testing date after injection. Thus, I max cannot be used to estimate the influence of gating on EC 50 . Because most mutants have the I max values that were not dramatically reduced, the contribution of gating influence on EC 50 are relatively small in these mutants. However, we noted that Y106SϩF138YϩV140LϩFYS240VF and Y102FϩY106SϩF138YϩV140LϩFYS240VF 1 mutants have relatively low expression. This is further confirmed by comparison of their expression levels to the wild-type receptor in the same batch of oocytes and in the same time period after injection. The results showed that the I max values for Y106SϩF138YϩV140LϩFYS240VF and Y102FϩY106SϩF138YϩV140LϩFYS240VF were 13 and 15% of the wild type expression level respectively. the combined mutation of these residues converted the 1 GABA receptor to the GABA A R antagonist pharmacology. 3-APMPA has a structure similar to that of 3-APA. Using high concentrations of 3-APMPA to test all mutants is costprohibitive. Thus, we tested only its sensitivity in the quintuple mutant. Indeed, the quintuple mutant also exhibited insensitivity to 3-APMPA. At the concentration of 1500 M, 3-APMPA only inhibited the GABA-induced current by approximately 30% (data not shown). Thus, residues Tyr102, Phe138, Val140, and potentially Tyr241 are important determinant for 3-APA and 3-APMPA binding.
Corresponding Mutants in GABA A R Partially Converted the Receptor to GABA C Pharmacology. If the identified residues in GABA C R are major determinants for its antagonist specificity, we should expect that mutations of these residues in GABA A R also convert its pharmacological properties to GABA C R. In the GABA A R, loops A and C are in the ␤ subunit, whereas loop D is in the ␣ subunit. The three mutants corresponding to the Y106S, F138Y, and FYS240VF in the 1 GABA C R for bicuculline sensitivity are ␣ 1 (S68Y), ␤ 2 (Y97F), and ␤ 2 (VF199FYS). In fact, single mutations of ␣ 1 (S68Y) or ␤ 2 (Y97F) reduced the receptor sensitivity to bicuculline (Table 2 and Fig. 5A ). Thus, ␣ 1 Ser68 and ␤ 2 Tyr97 are important determinants of GABA A R bicuculline sensitivity. In contrast, the mutant ␤ 2 VF199FYS in the loop C slightly increased bicuculline sensitivity (Table 2 ). This opposite effect will be discussed in more detail under Discussion. When the quintuple mutant (triple mutant ␤ 2 subunit coexpressed with the double mutant ␣ 1 subunit) in the GABA A R, corresponding to the quintuple mutant of the GABA C R in Fig. 4 , C and D, the receptor exhibited a significant reduction in bicuculline (Table 2 ) and gabazine (Fig.  5B ) sensitivity and became slightly sensitive to 3-APA (data not shown). The results further support the importance of these five binding residues for the GABA A and GABA C R antagonist properties.
Discussion
In search of the structural basis of the distinct antagonist properties of GABA A and GABA C Rs, we have identified several key binding residues in loops D, A, and C as major determinants for GABA C R antagonist specificity. The results revealed that bicuculline sensitivity was mainly conferred by the mutations Y106S, F138Y, and FYS240VF. Gabazine sensitivity was highly dependent on the mutations Y106S, F138Y, and Y102F. For the GABA C R antagonist 3-APA, its sensitivity was mainly dependent on residues Tyr102, Val140, FYS240 -242, and Phe138. Thus, the residues Tyr102, Tyr106, Phe138, and FYS240 -242 in the 1 GABA C R are major determinants for the GABA C R antagonist properties distinct from those in the GABA A R. In addition, Val140 in the GABA C R also contributes to the 3-APA binding. To gain further insights from our findings, we performed homology modeling and ligand docking for both GABA A and GABA C Rs and provided further experimental evidence to dissect individual contribution of FYS240 -242.
Bicuculline Sensitivity. We have successfully docked bicuculline into the putative GABA A R binding pocket but failed in docking bicuculline into the GABA C R binding pocket. Figure   6A shows the docked bicuculline in the GABA A R binding pocket. Note that three putative hydrogen bonds are formed between the docked bicuculline molecule and residues ␤ 2 Tyr97 (loop A), ␤ 2 Tyr157 (loop B), or ␣ 1 Arg66 (loop D). Interaction of bicuculline to ␤ 2 Tyr97 is supported by that a single ␤ 2 Y97F mutation dramatically reduced the GABA A R sensitivity to bicuculline (Table 2, Fig. 5A ). The homologous residue in the GABA C R is 1 Phe138. However, the F138Y mutation only slightly increased the GABA C R affinity to bicuculline, presumably by forming a hydrogen bond with bicuculline. Thus, other residues must make substantial contributions to the bicuculline insensitivity of GABA C R. ␤ 2 Tyr157 and ␣ 1 Arg66 of GABA A R are binding residues (Amin and Weiss, 1993; Harrison and Lummis, 2006) . They are the same as their homologs 1 Tyr198 and 1 Arg104 in the 
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To further dissect contributions of individual residues in the FYS240FY mutant in loop C, we first examined the homology model of GABA C R. The loop C of the GABA C R has two aromatic residues, Phe240 and Tyr241 (a binding residue). The corresponding region in GABA A R has only one phenylalanine aligned to Tyr241. In addition, the position of these two aromatic residues could be altered by one insertion, Ser242. In the model, both residues (Phe240 and Tyr241) are lining the binding pocket. Because bicuculline is a large molecule, it is possible that this additional aromatic residue, Phe240, provides a steric hindrance for bicuculline binding. In fact, virtual F240V mutation in the GABA C R homology model increased the size of the binding pocket. Consequently, we were able to dock the bicuculline into the binding pocket of this mutant GABA C R model (data not shown). This effect was confirmed experimentally; whereas GABA sensitivity of the 1 F240V mutant was similar to that of the wild type (but with a substantially reduced efficacy), this mutant did exhibit bicuculline sensitivity (K i ϭ 67.4 Ϯ 0.5 M). This further supports the notion that Phe240 in GABA C provides steric hindrance for bicuculline binding. In contrast, Y241F mutant remained insensitive to bicuculline (data not shown), suggesting that 1 Tyr241 does not contribute to bicuculline insensitivity. Note that the reverse mutation in the GABA A R (␤ 2 VF199FYS) did not reduce bicuculline sensitivity. In the GABA C R binding pocket, a residue near the Phe240 is the Asp219 in loop F. This negatively charged residue may provide electrostatic repulsion to the bicuculline, because the homologous residue in GABA A R is ␣ 1 Ala181, a small and noncharged residue. Thus, it may need both Phe240 and Asp219 acting collaboratively to narrow the bottom of the binding pocket, preventing bicuculline binding.
As for Tyr106 in loop D, 1 Y106S mutation improved sensitivity to bicuculline. The reverse mutation in the GABA A R (␣ 1 S68Y) reduced bicuculline sensitivity (Table 2) .
1 Tyr106 is next to Arg104, which is equivalent to ␣ 1 R66 (making hydrogen bonding to bicuculline). It is possible that steric hindrance of loop C in the GABA C R pushes bicuculline to an upper position (Y106S), shifting hydrogen bonding from Arg104 to Y106S. The bulky Tyr106 may protrude too far so that it cannot form a hydrogen bond to bicuculline. However, when it was mutated to serine, the distance to bicuculline became closer.
Influence of Other Nearby Residues
Although addition of Y102F and Val140L mutations to the triple mutant further decreased 3-APA sensitivity, it also unexpectedly resulted in a decrease in bicuculline sensitivity. This reduction could partially due to gating effect because the quadruple and quintuple Table 4 . C, effect of quintuple mutations on 3-APA sensitivity. Because of limited inhibition, fitting was not performed. Straight lines are used to link multiple points. mutants exhibited significantly reduced maximal current (Table 1). We re-tested I max values in the quadruple and quintuple mutants and compared them with the wild type (Table 1 leg end) . Both mutants exhibited approximately a 7-fold reduction of I max . Three-binding-to-open model (Amin and Weiss, 1996; Chang et al., 2000) predicts that EC 50 shift due to this I max reduction could account for ϳ2.7-fold increase in EC 50 value. Thus, the calculated K i could be underestimated by ϳ2-fold as a result of reduction of gating efficiency. In addition, trivial contributions of many other nearby nonbinding residues may influence the conformation in the binding site, making the GABA A R more sensitive to bicuculline.
Gabazine Sensitivity. Our results suggest that Tyr102, Tyr106, and Phe138 are important residues that make the ϾϾ, inhibition was 20 to 40% at the concentration indicated; Ͼ, inhibition was between 40 to 50% at the concentration indicated.
Fig. 5.
Mutations of the GABA A R in the corresponding residues partially converted the receptor to GABA C antagonist properties. A, effect of mutations of the GABA A R on bicuculline sensitivity. The GABA receptor ␤ 2 Y97F mutation resulted in more than 10-fold decrease in bicuculline sensitivity. Coexpression of this mutant with the ␣ 1 S68Y mutant resulted in further reduction in bicuculline sensitivity. This further reduction of bicuculline sensitivity was counteracted by adding the third mutation ␤ 2 VF199FYS to the receptor. The dashed line represents the normalized dose-inhibition of GABA-induced current by bicuculline in the wild-type GABA A R. B, the quintuple mutant of the GABA A R to their homologous residues in the 1 GABA C R reduced gabazine sensitivity. Top, an example of a GABA-induced current inhibited by increasing concentrations of gabazine. Bottom, normalized and averaged dose-inhibition of the GABA-induced current by gabazine. Continuous line is the best fit of the data to a Hill inhibition equation. The resulting IC 50 is listed in Table 3 . Dashed line represents the normalized dose-inhibition of GABA-induced current by gabazine in the wild type GABA A R.
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molpharm.aspetjournals.org GABA C R less sensitive to gabazine, and FYS240VF is not important for gabazine sensitivity. The result is consistent with a previous finding in the GABA A R: ␣ 1 F64 (homologous to 1 Tyr102) and ␤ 2 Tyr97 (homologous to 1 Phe138) are binding residues for gabazine (Boileau et al., 2002; Holden and Czajkowski, 2002) . To get structural insights into the mechanism, we successfully docked gabazine molecule into the binding pockets of both GABA A and GABA C receptors with higher docking score in the GABA A R. Figure 6B is the docked gabazine to the GABA A R binding pocket. Four putative hydrogen bonds were identified between the docked gabazine and four residues in loops A (␤ 2 Tyr97), B (␤ 2 Glu155 and ␤ 2 Tyr157) and C (␤ 2 Ser201). ␤ 2 Tyr97 is homologous to 1 Phe138. Thus, this conserved Y3F mutation potentially eliminates one hydrogen bonding, making the GABA C R less sensitive to gabazine. ␤ 2 Glu155 and ␤ 2 Tyr157 are important binding residues in the GABA A R (Amin and Weiss, 1993; Newell et al., 2004) . The residues corresponding to ␤ 2 Glu155, ␤ 2 Tyr157, and ␤ 2 Ser201 in the 1 subunit are Glu196, Tyr198, and Ser243 (or Ser242 because of an insertion of a serine). Because of identical residues at these positions in both GABA A R and GABA C R, they are not under our consideration. It is noteworthy that 1 Y102F significantly increased the apparent affinity to gabazine. Using the structural model of GABA A R as a reference, we speculate that the nature of interaction between ␣ 1 F64 and gabazine is most likely a hydrophobic interaction. Thus, a more hydrophilic tyrosine at this position of the 1 GABA C R would substantially weaken this interaction. As for 1 Tyr106 (␣ 1 Ser68), the docked gabazine in the GABA A R model could not reach ␣ 1 Ser68 in all poses. However, the docked gabazine in the GABA C R binding pocket exhibited a clockwise rotation, bringing the top of the molecule to the vicinity of Tyr106 or its mutant Y106S (data not shown) while maintaining the contact with Tyr102. Thus, in the complex interacting network, ligand docking position can be altered by other available interactions. Finally, FYS240VF is not important for gabazine sensitivity, probably because phenylalanine no longer provides steric hindrance to the smallersized gabazine. 3-APA and 3-APMPA Sensitivity. Compared with bicuculline and gabazine, 3-APA and 3-APMPA are much smaller molecules. Our results suggest that 3-APA apparent affinity was reduced substantially by four mutations of Y102F, V140L, FYS240VF, and F138Y (Table 4) . Thus, the binding site must be located in the vicinity of these four positions. Figure 6C represents a pose with 3-APA docked into an aromatic box formed by Phe138, Phe240, Tyr241, and Tyr102 [and Tyr247 and Tyr198 (behind) ]. However, Val140 is not in direct contact with 3-APA. It is possible that mutation of this valine to a larger residue leucine would provide a steric hindrance to the binding and result in a decreased binding affinity for 3-APA. The amino group of the 3-APA also potentially forms a hydrogen bond with Glu196, which is homologous to ␤ 2 Glu155 in the GABA A R. With the aromatic box surrounding the docked 3-APA, it is possible that there is a -cation interaction between 3-APA and a nearby aromatic residue(s). Thus, the binding of 3-APA to the GABA C R could Fig. 6 . Structural models of the GABA A or GABA C R amino-terminal domains docked with antagonists. A, bicuculline docked to the GABA A R binding pocket. Note that the docked bicuculline formed hydrogen bonds with three residues in loops A (␤ 2 Tyr97), D (␣ 1 Arg66), and B (␤ 2 Tyr157) (not visible in this view), and was also in close vicinity to ␣ 1 Ser68. B, gabazine docked to the GABA A R binding pocket. Note that the docked gabazine molecule formed hydrogen bonding with four residues in loops A (␤ 2 Y97), B (␤ 2 Glu155 and ␤ 2 Tyr157), and C (␤ 2 Ser201). C, 3-APA docked to GABA C R binding pocket. The docked 3-APA molecule can form a hydrogen bond with Glu196 in loop B of the 1 GABA receptor subunit, homologous to ␤ 2 Glu155 in the GABA A R. Note that the docked 3-APA resided in the aromatic box formed by Phe138, Phe240, Tyr241, and Tyr102 [and Tyr247 and Tyr198 (behind)]. be very similar to the binding of GABA to the receptor (Lummis et al., 2005) . Lacking an aromatic residue in the GABA A R at the position homologous to Phe240 could reduce 3-APA affinity. 3-APMPA has structure similar to that of 3-APA. Parallel affinity reduction with these mutations for 3-APA and 3-APMPA also suggests that the structural requirements of their binding to the GABA C R are similar. Reverse mutation of the GABA A R only slightly increased 3-APA affinity suggesting other residues also make a significant contribution to the 3-APA binding.
In summary, we have identified important residues in three binding loops responsible for the GABA C R antagonist properties distinct from those of GABA A R. The insights gained from this study can aid design of new antagonists for the GABA A and GABA C receptors. The approach we used in this study can also be applied to examine the mechanisms of agonist/antagonist specificity among the GABA A R subtypes.
